Glucagon-like peptide-1 receptor agonists or sodium–glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints Επικοινωνία Submitted by Χριστόδουλος Π… on Πέμ, 11/12/2020 - 12:58
